Pharmaceutical News and Articles

Minor Complications Up for Black Patients After Weight-Loss Surgery

Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study presented at the annual meeting of the

Deep Sleep, Daytime Control Key to Nocturnal Enuresis Management

Specific factors, including deep sleep and daytime urinary control, are associated with treatment-responsive nocturnal enuresis among children, according to a s

Gluten-Stimulated Interleukin-2 Secretion Useful for Diagnosing Celiac Disease

Gluten-stimulated interleukin-2 (IL-2) secretion is useful for diagnosis of celiac disease (CeD), according to a study published online June 9 in Gastroenterolo

Hydrops MRI Accurately Differentiates Meniere Disease, Vestibular Migraine

The combination of cochlear endolymphatic hydrops (CEH) and vestibular endolymphatic hydrops (VEH) on magnetic resonance imaging (MRI) accurately diagnoses Meni

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphom

Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profile Consistent with Injectable GLP-1 Medicines, in Complete Phase 3 Results

Eli Lilly and Company (NYSE LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to

Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safety Profile Consistent with Daily Insulin in Multiple Phase 3 Trials

Eli Lilly and Company (NYSE LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy

Novo Nordisk's Mim8 Prophylaxis Treatment Shown to be Well-Tolerated When Switching from Emicizumab in People with Hemophilia A in New Phase 3 Data

Bagsv rd, Denmark, 22 June 2025 Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (den

Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)